CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for age-related neurologic disorders, announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference in New York on October 9, 2024. Dr. John Alam, CEO of CervoMed, will take part in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications' at 8:00am ET.
The conference provides CervoMed with a platform to engage with investors through one-on-one meetings, potentially increasing visibility for the company's innovative approach to addressing age-related neurologic disorders. This event offers an opportunity for CervoMed to showcase its progress and strategy in pursuing significant market opportunities within the healthcare sector.
CervoMed Inc. (NASDAQ: CRVO), un'azienda in fase clinica che sviluppa trattamenti per disturbi neurologici legati all'età, ha annunciato la sua partecipazione alla 3ª Annual ROTH Healthcare Opportunities Conference a New York il 9 ottobre 2024. Il Dr. John Alam, CEO di CervoMed, parteciperà a una tavola rotonda dal titolo 'Opportunità e sfide quando piccoli nomi puntano a indicazioni di grande successo' alle 8:00 ET.
La conferenza offre a CervoMed una piattaforma per interagire con gli investitori attraverso incontri individuali, aumentando potenzialmente la visibilità dell'approccio innovativo dell'azienda per affrontare i disturbi neurologici legati all'età. Questo evento rappresenta un'opportunità per CervoMed di mostrare i suoi progressi e la sua strategia nel perseguire opportunità di mercato significative nel settore sanitario.
CervoMed Inc. (NASDAQ: CRVO), una empresa en etapa clínica que desarrolla tratamientos para trastornos neurológicos relacionados con la edad, anunció su participación en la 3ª Conferencia Anual de Oportunidades en Salud de ROTH en Nueva York el 9 de octubre de 2024. El Dr. John Alam, CEO de CervoMed, participará en un panel titulado 'Oportunidades y desafíos cuando nombres pequeños buscan indicaciones de gran éxito' a las 8:00 am ET.
La conferencia proporciona a CervoMed una plataforma para interactuar con inversores a través de reuniones individuales, aumentando potencialmente la visibilidad del enfoque innovador de la empresa para abordar los trastornos neurológicos relacionados con la edad. Este evento ofrece una oportunidad para que CervoMed muestre su progreso y estrategia en la búsqueda de oportunidades de mercado significativas dentro del sector de la salud.
CervoMed Inc. (NASDAQ: CRVO), 노화 관련 신경 장애를 위한 치료제를 개발하는 임상 단계 기업이 제3회 연례 ROTH 헬스케어 기회 회의에 참여한다고 발표했습니다. 이 회의는 2024년 10월 9일 뉴욕에서 열리며, CervoMed의 CEO인 John Alam 박사가 '소규모 기업이 블록버스터 적응증을 추구할 때의 기회와 도전'이라는 제목의 패널 토론에 참여할 예정입니다. 시간은 동부 표준시로 오전 8시입니다.
이번 회의는 CervoMed에게 투자자와의 일대일 미팅을 통해 소통할 수 있는 기회를 제공하며, 회사의 노화 관련 신경 장애 접근 방식에 대한 가시성을 높일 수 있는 잠재적인 방법입니다. 이 행사는 CervoMed가 의료 분야 내에서 중요한 시장 기회를 추구하는 과정과 전략을 보여줄 수 있는 기회를 제공합니다.
CervoMed Inc. (NASDAQ: CRVO), une entreprise en phase clinique développant des traitements pour des troubles neurologiques liés à l'âge, a annoncé sa participation à la 3ème Conférence Annuelle sur les Opportunités en Santé de ROTH à New York le 9 octobre 2024. Le Dr John Alam, PDG de CervoMed, participera à une table ronde intitulée 'Opportunités et défis lorsque de petites entreprises aspirent à des indications de blockbuster' à 8h00 ET.
La conférence offre à CervoMed une plateforme pour dialoguer avec les investisseurs à travers des réunions individuelles, ce qui pourrait accroître la visibilité de l'approche innovante de l'entreprise pour traiter les troubles neurologiques liés à l'âge. Cet événement représente une occasion pour CervoMed de mettre en avant ses progrès et sa stratégie dans la recherche d'opportunités de marché significatives dans le secteur de la santé.
CervoMed Inc. (NASDAQ: CRVO), ein Unternehmen in der klinischen Phase, das Behandlungen für altersbedingte neurologische Störungen entwickelt, gab seine Teilnahme an der 3. jährlichen ROTH Healthcare Opportunities Conference in New York am 9. Oktober 2024 bekannt. Dr. John Alam, CEO von CervoMed, wird an einer Podiumsdiskussion mit dem Titel 'Chancen und Herausforderungen, wenn kleine Unternehmen nach Blockbuster-Indikationen streben' um 8:00 Uhr ET teilnehmen.
Die Konferenz bietet CervoMed eine Plattform, um über persönliche Gespräche mit Investoren in Kontakt zu treten, was potenziell die Sichtbarkeit des innovativen Ansatzes des Unternehmens zur Behandlung altersbedingter neurologischer Störungen erhöhen könnte. Diese Veranstaltung bietet CervoMed die Gelegenheit, seine Fortschritte und Strategien bei der Verfolgung signifikanter Marktchancen im Gesundheitssektor zu präsentieren.
- None.
- None.
Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”
BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John Alam, Chief Executive Officer, is scheduled to participate in a panel discussion and one-on-one investor meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, being held in New York, NY, on October 9, 2024.
Panel Details
Title: “Opportunities and Challenges When Small Names Go After Blockbuster Indications”
Date: Wednesday, October 9, 2024
Time: 8:00am ET
About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (CRVO) participating in the ROTH Healthcare Opportunities Conference?
What panel is CervoMed's CEO participating in at the ROTH conference?
What is the focus of CervoMed's (CRVO) clinical research?
Will CervoMed (CRVO) be conducting investor meetings at the ROTH conference?
